Headlands Technologies LLC Sells 34,924 Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Headlands Technologies LLC decreased its holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 63.4% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 20,185 shares of the biotechnology company’s stock after selling 34,924 shares during the quarter. Headlands Technologies LLC’s holdings in Ironwood Pharmaceuticals were worth $89,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Charles Schwab Investment Management Inc. lifted its stake in Ironwood Pharmaceuticals by 23.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,904,271 shares of the biotechnology company’s stock worth $7,846,000 after purchasing an additional 364,841 shares during the period. FMR LLC lifted its position in shares of Ironwood Pharmaceuticals by 25.1% during the 3rd quarter. FMR LLC now owns 169,681 shares of the biotechnology company’s stock worth $699,000 after buying an additional 34,089 shares during the period. BNP Paribas Financial Markets boosted its stake in Ironwood Pharmaceuticals by 89.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 154,660 shares of the biotechnology company’s stock valued at $637,000 after buying an additional 72,815 shares in the last quarter. Quantinno Capital Management LP raised its stake in Ironwood Pharmaceuticals by 40.0% during the third quarter. Quantinno Capital Management LP now owns 19,191 shares of the biotechnology company’s stock worth $79,000 after acquiring an additional 5,482 shares in the last quarter. Finally, State Street Corp raised its stake in Ironwood Pharmaceuticals by 7.3% during the third quarter. State Street Corp now owns 9,919,865 shares of the biotechnology company’s stock worth $40,870,000 after acquiring an additional 677,024 shares in the last quarter.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on IRWD shares. StockNews.com raised shares of Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, March 29th. Craig Hallum decreased their price objective on shares of Ironwood Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Wednesday, January 22nd. Finally, JMP Securities dropped their price objective on shares of Ironwood Pharmaceuticals from $23.00 to $14.00 and set a “market outperform” rating for the company in a report on Thursday, January 30th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $8.60.

Insider Transactions at Ironwood Pharmaceuticals

In related news, CMO Michael Shetzline sold 41,269 shares of Ironwood Pharmaceuticals stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $1.76, for a total value of $72,633.44. Following the completion of the sale, the chief marketing officer now directly owns 554,007 shares in the company, valued at $975,052.32. This trade represents a 6.93 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Thomas A. Mccourt sold 139,064 shares of the company’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $1.76, for a total transaction of $244,752.64. Following the transaction, the chief executive officer now owns 1,160,634 shares in the company, valued at approximately $2,042,715.84. The trade was a 10.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 192,381 shares of company stock worth $338,591 over the last 90 days. 12.90% of the stock is owned by insiders.

Ironwood Pharmaceuticals Stock Down 1.5 %

Shares of NASDAQ:IRWD opened at $1.34 on Monday. The firm has a market cap of $214.44 million, a P/E ratio of -44.67 and a beta of 0.30. Ironwood Pharmaceuticals, Inc. has a 12 month low of $1.25 and a 12 month high of $8.45. The company’s 50-day moving average price is $1.81 and its two-hundred day moving average price is $3.27.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.08). Ironwood Pharmaceuticals had a negative net margin of 0.65% and a negative return on equity of 0.96%. The company had revenue of $90.55 million for the quarter, compared to the consensus estimate of $93.85 million. As a group, equities analysts predict that Ironwood Pharmaceuticals, Inc. will post 0.1 earnings per share for the current fiscal year.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.